Chronic PDE-5 inhibition in patients with erectile dysfunction - A treatment approach using tadalafil once-daily

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 10, 2012, Pages 1481-1494

  Porst, Hartmut ^a   Hell Momeni, Katja ^b   Büttner, Hartwig ^b  

^a Urology and Andrology Center   (Germany)

^b LILLY DEUTSCHLAND GMBH   (Germany)

Author keywords

Chronic PDE 5 inhibition; Endothelial dysfunction; Erectile dysfunction; Review; Tadalafil

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; NITRIC OXIDE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; TADALAFIL; VARDENAFIL;

AREA UNDER THE CURVE; ARTICLE; BACKACHE; BRONCHITIS; CARDIOVASCULAR RISK; COLOR VISION DEFECT; DIZZINESS; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; ERECTILE DYSFUNCTION; FLUSHING; FOOD DRUG INTERACTION; GASTROESOPHAGEAL REFLUX; HEADACHE; HEART PROTECTION; HUMAN; HYPERTENSION; INFLUENZA; ISCHEMIC OPTIC NEUROPATHY; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NONARTERITIC ISCHEMIC OPTIC NEUROPATHY; NOSE CONGESTION; PATHOGENESIS; PATIENT SATISFACTION; PENIS ERECTION; PERCEPTION DISORDER; PULMONARY HYPERTENSION; RHINITIS; RHINOPHARYNGITIS; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE; SIDE EFFECT; SINUS CONGESTION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; VASODILATATION; VIRAL GASTROENTERITIS;

CARBOLINES; DRUG ADMINISTRATION SCHEDULE; ERECTILE DYSFUNCTION; HUMANS; MALE; PHOSPHODIESTERASE 5 INHIBITORS;

EID: 84863090509     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.693162     Document Type: Article

References (76)

1. Braun M, Wassmer G, Klotz T, et al. Epidemiology of erectile dysfunction: Results of the 'Cologne Male Survey'. Int J Impot Res 2000;12:305-11
2. McKinlay JB. the worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res 2000;12(Suppl 4):S6-11
3. Althof SE. Quality of life and erectile dysfunction. Urology 2002;59:803-10
4. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61
5. Porst H, Sharlip H. History and epidemiology of male sexual dysfunction. In: Porst H, Buvat J, editors. Standard Practice in Sexual Medicine. Blackwell; Oxford: 2006
6. Montorsi F, Briganti A, Salonia A, et al. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol 2003;44:360-5
7. Montorsi P, Ravagnani PM, Galli S, et al. Association between erectile dysfunction and coronary artery disease: Matching the right target with the right test in the right patient. Eur Urol 2006;50:721-31
8. Montorsi F, Adaikan G, Becher E, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2010;7:3572-88
9. Jensen J, Lendorf A, Stimpel H, et al. the prevalence and etiology of impotence in 101 male hypertensive outpatients. Am J Hypertens 1999;12:271-5
10. Bacon CG, Hu FB, Giovannucci E, et al. Association of type and duration of diabetes with erectile dysfunction in a large cohort of men. Diabetes Care 2002;25:1458-63
11. Jackson G, Boon N, Eardley I, et al. Erectile dysfunction and coronary artery disease prediction: evidence-based guidance and consensus. Int J Clin Pract 2010;64:848-57
12. Thompson IM, Tangen CM, Goodman PJ, et al. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005;294:2996-3002
13. El-Sakka AI, Morsy AM. Screening for ischemic heart disease in patients with erectile dysfunction: Role of penile Doppler ultrasonography. Urology 2004;64:346-50
14. Chiurlia E, D'Amico R, Ratti C. Subclinical coronary artery atherosclerosis in patients with erectile dysfunction. J Am Coll Cardiol 2005;46:1503-6
15. Kirby M, Jackson G, Simonsen U. Endothelial dysfunction links erectile dysfunction to heart disease. Int J Clin Pract 2005;59:225-9
16. Vlachopoulos C, Aznaouridis K, Ioakeimidis N, et al. Unfavourable endothelial and inflammatory state in erectile dysfunction patients with or without coronary artery disease. Eur Heart J 2006;27:2640-8
17. Montorsi P, Montorsi F, Schulman CC. Is erectile dysfunction the 'tip of the iceberg' of a systemic vascular disorder? Eur Urol 2003;44:352-4
18. Vita JA, Keaney JF, Larson MG, et al. Brachial artery vasodilator function and systemic inflammation in the Framingham Offspring Study. Circulation 2004;110:3604-9
19. Clapp BR, Hingorani AD, Kharbanda RK, et al. Inflammation-induced endothelial dysfunction involves reduced nitric oxide bioavailability and increased oxidant stress. Cardiovasc Res 2004;64:172-8
20. Saenz de Tejada I, Goldstein I, Azadzoi K, et al. Impaired neurogenic and endothelium mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med 1989;320:1025-30
21. Ignarro LJ, Bush PA, Buga GM, et al. Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun 1990;170:843-50
22. Moncada Iribarren I, Saemu de Tejada I. Vascular physiology of penile erection. In: Carson C, Kirby R, Goldstein I, editors. Textbook of erectile dysfunction. Isis Medical Media; Oxford: 1999
23. Vallance P, Chan N. Endothelial function and nitric oxide: Clinical relevance. Heart 2001;85:342-50
24. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use. Pharmacol Rev 2006;58:488-520
25. Zhang X, Feng Q, Cote RH. Efficacy and selectivity of phosphodiesterase-targeted drugs in inhibiting photoreceptor phosphodiesterase (PDE6) in retinal photoreceptors. Invest Ophthalmol Vis Sci 2005;46:3060-6
26. Porst H, Sharlip ID, Hatzichristou D, et al. Extended duration of efficacy of vardenafil when taken 8 h before intercourse: A randomized, double-blind, placebo-controlled study. Eur Urol 2006;50:1094-5
27. McCullough AR, Steidle CP, Klee B, et al. Randomized, double-blind, crossover trial of sildenafil in men with mild to moderate erectile dysfunction: efficacy at 8 and 12 h postdose. Urology 2008;71:686-92
28. Porst H, Padma-Nathan H, Giuliano F, et al. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 h after dosing: A randomized controlled trial. Urology 2003;62:121-5
29. Carson CC. the efficacy and safety of tadalafil: An update. BJU Int 2004;93:1276-81
30. Forgue ST, Patterson BE, Bedding AW, et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2006;61:280-8
31. Carson CC, Burnett AL, Levine LA, et al. the efficacy of sildenafil citrate (Viagra) in clinical populations: An update. Urology 2002;60(2 Suppl 2):12-27
32. Goldstein I, Lue TF, Padma-Nathan H, et al. Sildenafil Study Group. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998;338:1397-404
33. Porst H, Rosen R, Padma-Nathan H, et al. the efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: The first at-home clinical trial. Int J Impot Res 2001;13:192-9
34. Brock GB, McMahon CG, Chen KK, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: Results of integrated analyses. J Urol 2002;168:1332-6
35. Rubio-Aurioles E, Porst H, Eardley I, et al. Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: A randomized, double-blind, pooled crossover study. J Sex Med 2006;3:1037-49
36. Tolra JR, Campana JM, Ciutat LF, Miranda EF. Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors. J Sex Med 2006;3:901-9
37. Rodriguez Vela L, Lledo Garcia E, Rajmil O, et al. Tadalafil vs sildenafil patient preference in Spanish men with erectile dysfunction: Results from an International Multicentric Study. Actas Urol Esp 2006;30:67-79
38. Eardley I, Mirone V, Montorsi F, et al. An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy. BJU Int 2005;96:1323-32
39. Dean J, Hackett GI, Gentile V, et al. Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: Results of a multicenter, randomized, open-label, crossover study. J Sex Med 2006;3:650-61
40. Sommer E, Klotz T, Mathers M, et al. A comparative multicentre study of the maximum dose of sildenafil, tadalafil and vardenafil. Eur Urol 2004;45(Suppl 3):abstract 410
41. Porst H, Kleingarn M, Arnds S. the two PDE-5 inhibitors sildenafil and tadalafil - results of an independent intraindividual comparative trial. Eur Urol 2004;45(Suppl 3):abstract 99
42. von Keitz A, Rajfer J, Segal S, et al. A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil. Eur Urol 2004;45:499-507
43. Porst H, Arnds S, Kleingarn M. the 3 PDE5 inhibitors sildenafil, tadalafil and vardenafil: Results of an independent intraindividual comparative study. Eur Urol 2004;45(Suppl 3):abstract 408
44. Govier F, Potempa AJ, Kaufman J, et al. A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction. Clin Ther 2003;25:2709-23
45. Stroberg P, Murphy A, Costigan T. Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: Results of a European multicenter, open-label study of patient preference. Clin Ther 2003;25:2724-37
46. Laties A, Sharlip I. Ocular safety in patients using sildenafil citrate therapy for erectile dysfunction. J Sex Med 2006;3:12-27
47. Kloner RA, Hutter AM, Emmick JT, et al. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol 2003;42:1855-60
48. Carson CC, Shabsigh R, Segal S, et al. Efficacy, safety, and treatment satisfaction of tadalafil versus placebo in patients with erectile dysfunction evaluated at tertiary-care academic centers. Urology 2005;65:353-9
49. Ballard SA, Gingell CJ, Tang K, et al. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase enzymes. J Urol 1998;159:2164-71
50. Wrishko R, Sorsaburo S, Wong D, et al. Safety, efficacy and pharmacokinetic overview of low-dose daily administration of tadalafil. J Sex Med 2009;6:2039-48
51. Porst H, Giuliano F, Glina S, et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 and 10 mg in the treatment of erectile dysfunction: Results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol 2006;50:351-9
52. Montorsi F, Verheyden B, Meuleman E, et al. Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction. Eur Urol 2004;45:339-44
53. Vernet D, Magee T, Qian A, et al. Phosphodiesterase type 5 is not upregulated by tadalafil in cultures of human penile cells. J Sex Med 2006;3:84-94
54. McMahon C. Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med 2005;2:415-25
55. Dunn ME, Althof SE, Perelman MA. Phosphodiesterase type 5 inhibitors' extended duration of response as a variable in the treatment of erectile dysfunction. Int J Impot Res 2007;19:119-23
56. Seftel AD, Buvat J, Althof SE, et al. Improvements in confidence, sexual relationship and satisfaction measures: Results of a randomized trial of tadalafil 5mg taken once daily. Int J Impot Res 2009;21:240-8
57. Althof SE, Eid JF, Talley DR, et al. Through the eyes of women: The partners' perspective on tadalafi. Urology 2006;68:631-5
58. Althof SE, Rubio-Aurioles E, Kingsberg S, et al. Impact of tadalafil once daily in men with erectile dysfunction - including a report of the partners' evaluation. Urology 2010;75:1358-63
59. Rosano GM, Aversa A, Vitale C, et al. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 2005;47:214-20
60. Sorensen KE, Celermajer DS, Spiegelhalter DJ. Non-invasive measurement of human endothelium dependent arterial responses: Accuracy and reproducibility. Br Heart J 1995;74:247-53
61. Foresta C, Ferlin A, De Toni L, et al. Circulating endothelial progenitor cells and endothelial function after chronic tadalafil treatment in subjects with erectile dysfunction. Int J Impot Res 2006;18:484-8
62. Dimmeler S, Zeiher AM. Vascular repair by circulating endothelial progenitor cells: The missing link in atherosclerosis? J Mol Med 2004;82:671-7
63. Sesti C, Florio V, Johnson EG, Kloner RA. the phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size. Int J Impot Res 2007;19:55-61
64. Schwarz ER, Kapur V, Rodriguez J, et al. the effects of chronic phosphodiesterase-5 inhibitor use on different organ systems. Int J Impot Res 2007;19:139-48
65. McMahon C. Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. J Sex Med 2004;1:292-300
66. Porst H, Rajfer J, Casabe A, et al. Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction. J Sex Med 2008;5:2160-9
67. Aversa A, Bruzziches R, Pili M, et al. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: A pilot study. Int J Impot Res 2007;19:200-7
68. Rajfer J, Aliotta PJ, Steidle CP, et al. Tadalafil dosed once a day in men with erectile dysfunction: A randomized, double-blind, placebo-controlled study in the US. Int J Impot Res 2007;19:95-103
69. Seftel A, Goldfischer E, Kim ED, et al. Onset of efficacy of tadalafil taken once daily by men with erectile dysfunction: A randomized, double-blind, placebo-controlled trial. J Urol 2001;185:243-8
70. Shabsigh R, Donatucci C, Costabile R, et al. Reliability of efficacy in men with erectile dysfunction treated with tadalafil once daily after initial success. Int J Impot Res 2010;22:1-8
71. Schulman CC, Shen W, Stothard D, et al. Integrated analysis examining first-dose success, success by dose, and maintenance of success among men taking tadalafil for erectile dysfunction. Urology 2004;64:783-8
72. Zumbe J, Porst H, Sommer F, et al. Comparable effect of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction. Eur Urol 2008;54:204-12
73. Porst H, Glina S, Ralph D, et al. Durability of response following cessation of tadalafil taken once daily as treatment for erectile dysfunction. J Sex Med 2010;7:3487-94
74. Cordell WH, Maturi RK, Costigan TM, et al. for the ERG Testing During Chronic PDE5 Inhibitor Administration (ERG-PDE5i) Consortium. Retinal effects of 6 months of daily use of tadalafil or sildenafil. Arch Opthamol 2009;127:1-8
75. Jackson G, Kloner RA, Costigan TM, et al. Update on clinical trials of tadalafil demonstrates no increased risk of cardiovascular adverse events. J Sex Med 2004;1:161-7
76. Hatzichristou D, Gambla M, Rubio-Aurioles E, et al. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. Diabet Med 2008;25:138-46